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Ageing is associated with a general reduction of physiological function and a reduction of
muscle mass and strength. Endocrine factors such as myostatin, activin A, growth and
differentiation factor 11 (GDF-11) and their inhibitory peptides influence muscle mass
in health and disease. We hypothesised that myocytes cultured in plasma from older
and younger individuals would show an ageing effect, with reduced proliferation and
differentiation in older environments. C2C12 myoblasts were grown as standard and
stimulated with media conditioned with 5% plasma from healthy male participants that
were either younger (n = 6, 18–35 years of age) or older (n = 6, >57 years of age).
Concentration of plasma myostatin (total and free), follistatin-like binding protein (FLRG),
GDF-11 and activin A were quantified by ELISA. Both FLRG and activin A were elevated in
older individuals (109.6 and 35.1% increase, respectively), whilst myostatin (free and total)
and GDF-11 were not. Results indicated that plasma activin A and FLRG were increased
in older vs. younger participants, GDF11 and myostatin did not differ. Myoblasts in vitro
showed no difference in proliferation rate between ages, however scratch closure was
greater in younger vs. older plasma stimulated myoblasts (78.2 vs. 87.2% of baseline
scratch diameter, respectively). Myotube diameters were larger in cells stimulated with
younger plasma than with older at 24 and 48 h, but not at 2 h. A significant negative
correlation was noted between in vivo plasma FLRG concentration and in vitro myotube
diameter 48 h following plasma stimulation (r2 = 0.392, p = 0.030). Here we show that
myoblasts and myotubes cultured in media conditioned with plasma from younger or
older individuals show an ageing effect, and further this effect moderately correlates with
circulating FLRG concentration in vivo. The effect of ageing on muscle function may not
be innate to the tissue, but involve a general cellular environment change. Further work
is needed to examine the effect of increased FLRG concentration on muscle function in
ageing populations.
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INTRODUCTION
Human ageing is associated with a general decline in physiological function from the 3rd decade
onwards, including a loss of muscle mass and strength (Kallman et al., 1990). This reduction in
muscle mass and function is linked with reductions of independence, reduced metabolic health,
and an increase in all-cause mortality (Newman et al., 2001; Puts et al., 2005). Western society is
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experiencing an ageing population, with an increasing
proportion of society >65 years of age, and thus an increasing
need for understanding and treatment of the ageing-related loss
of muscle mass and function (Bloom et al., 2015).
This loss of muscle function does not result in muscle tissue
losing its plasticity and ability to respond to anabolic stimuli.
It is well-established that older individuals respond adequately
to resistance training with gains in muscle mass and strength
(Harridge et al., 1999; Liu and Latham, 2009). The effect of
ageing on total satellite cell number within muscles is unclear
to date (reviewed by Snijders et al., 2009). Reduced proliferation
rates are seen in satellite cells sourced from older muscle in
mice (Chakravarthy et al., 2000). However, primary cell culture
from biopsies of younger or older individuals do not differ in
their proliferative rate (Alsharidah et al., 2013), but may show
reduced fusion capacity when cultured in vitro (Pietrangelo et al.,
2009; Brzeszczynska et al., 2018). Further, when age-dependent
satellite cell proliferation capacity is seen in mice, the provision
of insulin-like growth factor (IGF) is capable of off-setting this
(Chakravarthy et al., 2000). These results suggest that the muscle
cells per-se maintain functionality in ageing, but the systemic
environment may instead be key.
Indeed, ageing is associated with changes in circulating factors
that are known to moderate muscle mass, including the growth
factors testosterone, growth hormone, and IGF (Ratkevicius
et al., 2011; Sellami et al., 2017) and pro-inflammatory cytokines
(Ferrucci et al., 2005; Alvarez-Rodríguez et al., 2012). The
transforming growth factor beta (TGF-β) family of signalling
peptides is relatively less studied. Myostatin (or growth and
differentiation factor 8, GDF8) is a TGF-β peptide familymember
that acts as a negative regulator of muscle mass (McPherron
et al., 1997). Myostatin circulates in an endocrine manner
(Zimmers et al., 2002), and this endocrine compartment of
myostatin correlates with muscle mass in humans across health
and disease states (Gonzalez-Cadavid et al., 1998). Closely related
peptide family members include activin A and growth and
differentiation family member 11 (GDF11). Indeed, GDF11’s
amino acid similarity is ∼90% relative to myostatin, despite
GDF11 acting on a wider range of tissues than myostatin,
including anterior posterior patterning during development,
visceral organ development and neural development (Walker
et al., 2016). Due in part to their structural similarity, circulating
myostatin, activin A and GDF11 share inhibitory binding
proteins, including follistatin, follistatin-like binding protein
(FRLG) and GDF-associated serum proteins 1 and 2 (GASP-1/2;
Nakamura et al., 1990; Hill et al., 2002; Amthor et al., 2004; Lee
and Lee, 2013).
Plasma myostatin peptide concentration does not appear to
change with age, despite older individuals showing reduced
muscle mass (Ratkevicius et al., 2011). Mixed reports exist as to
the changes in GDF11 with age, with one report of an increase
with age (Egerman et al., 2015), whilst another reports a decrease
(Sinha et al., 2014). We recently reported that chronically highly
active older individuals showed increased GDF11 concentration
over sedentary, aged matched controls (Elliott et al., 2017).
If the ageing process induces differences in these endocrine
factors and their inhibitory binding proteins, then this may
explain the loss of muscle mass and function with increasing
age. Thus, the aim of this experiment was to establish the
effect of cellular external environment on myocyte homeostasis
in vitro. It was hypothesised that myocytes in an older endocrine
environment would show reduced proliferative and growth
response, relative to those in a younger environment.
MATERIALS AND METHODS
The protocol was approved by the University of Westminster
Research Ethics sub-Committee. All participants gave written
informed consent in accordance with the Declaration of
Helsinki prior to their participation. Participants (n = 12) were
male, declared healthy, and equally divided into younger (n = 6,
18–35 years of age), or older (n = 6, >57 years of age. Age was
recorded to the nearest month (recorded in a decimal format,
e.g., 52 years 6 months= 52.5 years). Exclusion criteria including
regular (daily) smoking, clinically unstable conditions, and a
BMI < 18 or > 30.
Participants were requested to avoid strenuous activity for 24 h
and fast for 12 h prior to the morning of testing. Participants
presented at the research facility between 08:00 and 11:00 for
testing. Following measurement of height and weight (287 dp,
Seca, Germany) in minimal clothing, fat mass (FM), fat free
mass (FFM), and skeletal muscle mass (SkM) was quantified by
bioelectric impedance (mBCA 515, Seca, Germany). Participant
characteristics are summarised in Table 1.
Approximately 12mL of whole blood was then collected via
a convenient cubital vein in a standard manner into lithium
heparin coated tubes. Collected whole blood was immediately
spun (4◦C, 5 000 RPM, 10min) and resultant plasma was
aliquoted and stored at−80◦C for further testing.
Physical functionality of participants was assessed by hand
grip dynamometry (T.K.K. 5401, Takei Scientific Instruments,
Japan) and a 6min walk test (6MWT). For grip strength, each
participant stood with their dominant arm hanging straight
and semi-pronated (palm facing medially). Participants were
asked to give a maximal effort with verbal encouragement for
3 s, with 60 s between efforts. Grip strength was recorded three
times, with the maximal value reported here. The 6MWT was
performed in a standardmanner (ATS Committee on Proficiency
Standards for Clinical Pulmonary Function Laboratories, 2002)
on a pre-marked indoor track. A hand counter was used to record
distance, measured to the nearest meter.
Enzyme-Linked Immunosorbent Assays
Concentration of circulating myostatin within plasma (free and
total, DGDF80), activin A (DAC00B), FLRG (DFLRG0) and
GDF11 (DY1958) were measured by commercial ELISA (all R&D
Systems, UK). Briefly, plasma samples were brought to room
temperature before analysis. Total myostatin was measured by
acidification of plasma samples (100 µL plasma incubated with
50 µL 1M HCI for 10min at room temperature, then 50 µL of
1.2M NaOH/0.5M HEPES) and finally 200 µL calibrator diluent
(RD5-26) for a 1:4 dilution factor, whilst plasma samples for free
myostatin was diluted 1:4 in calibrator diluent, before resultant
mix was loaded at 100 µL per well, as we describe previously
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TABLE 1 | Participant characteristics, grouped into younger (n = 6) and older
(n = 6).
Younger Older P-value
Age (decimal years) 26.5 (1.5) 64.2 (2.1) <0.001
Body mass index 24.3 (0.3) 26.4 (1.6) 0.217
Fat mass (kg) 15.2 (2.5) 23.4 (2.5) 0.041
Fat free mass (kg) 61.7 (2.2) 55.3 (1.3) 0.032
SkM (kg) 30.1 (1.3) 26.3 (0.8) 0.028
Grip strength (kg) 46.6 (2.2) 38.6 (3.9) 0.102
6MWT (m) 629.3 (27.3) 551.8 (32.5) 0.098
BMI, Body mass index; SkM, skeletal muscle mass; 6MWT, 6min walk test. Significant
differences indicated by bolded p-values.
(Elliott et al., 2017). Activin A, FLRG and GDF11 were measured
with 100 µL of plasma loaded per well. Incubation times,
conditions and washes followed manufacturer’s instructions. All
plates were read at 450 nm and blanked to 570 nm (FLUROstar
Optima, BMG Labtech, UK). Recombinant myostatin (894410),
activin A (890709), FLRG (894136), and GDF11 (844380) was
used as standards, all provided by R&D (UK). All samples and
standards were measured in triplicates.
Cell Culture
Myoblasts from the established C2C12 cell line were seeded
(passage 11) into T75 flasks in triplicate in growth media (GM;
Dulbecco’s modified Eagle media with 10% fetal bovine serum,
penicillin and streptomycin) in standard conditions (37◦C, 5%
CO2,100% humidity) with media changed every 48 h until ∼
80% confluent for seeding into experimental conditions. All
experimental plates (described below) were seeded at an initial
density of ∼3.0 × 104 cells.mL−1. All in vitro experiments
described hereafter were performed with an n = 6 per group
(young or old) with each individual run in triplicate.
Cell Proliferation
To assess the effect of younger or older plasma on myoblast
proliferation, cells were seeded in 6 well plates in GM + 5%
plasma (younger or older). Cell proliferation was assessed at 24
and 48 h. Briefly, following aspiration of media and washing with
dPBS, cells were trypsinized (TrypLE, Gibco, 12605) for 5min
at 37◦C to ensure complete cell removal, then resuspended. Cell
counts per well wasmeasured in duplicate, utilising an automated
cell counter (Cell Countess II, Thermo Fisher, UK).
Scratch Assay
To assess the effect of younger or older plasma on myoblast
migration, cells were seeded in 6 well plates in GM, and
proliferated as standard until >80%. Scratch assays were
performed as described by Liang et al. (2007). Briefly, cells were
scratched once in a single, fluid motion using a sterile p200 tip
to remove a linear section of cells. Cells were then washed with
dPBS, before the addition of GM + 5% plasma (younger or
older). Cells were immediately photographed (10x, 1.3 megapixel
digital camera) in 3 random locations per scratch, then incubated
in standard conditions for 4 h before repeating photographs.
Scratch size was quantified in ImageJ (version 1.49, NIH, USA)
by an individual blinded to condition and time, and closure
calculated as percent of individual baseline.
Myotube Diameter
Following seeding in 6 well plates, myoblasts were grown to
∼80% confluency as standard. Near confluent cells were switched
to differentiation media (DM; Dulbecco’s modified Eagle media
with 2% horse serum, penicillin, and streptomycin), with DM
changed every 24 h for 96 h. Following this, cells were stimulated
with DM + 5% plasma (younger/older), and photographed
immediately in 3 random locations per plate, as described above.
Cells were further photographed at 4, 24, and 48 h in the same
manner. Cell diameter was quantified at three different locations
along the cells length, in 10 random cells per image, by an
individual blinded to condition and time utilising ImageJ.
Statistical Analysis
Normality of data was checked for by Shapiro–Wilk test.
Differences between younger and older characteristics, Activin A
and FLRG ELISA concentrations, and scratch assay results were
established by two-tailed, unpaired t-tests, whist effect of age on
GDF11 was established by a Mann Whitney test. Concentration
of total and free myostatin, cell proliferation, and myotube
diameters were compared with a mixed-model two-way repeated
measures ANOVA, with post hoc testing performed in themethod
of Bonferroni when indicated. Pearson’s correlation was used
to examine associations between endocrine factors that differed
between younger and older individuals and in vitro results. SPSS
(version 23, IBM) was used for all statistical analysis, and all
figures were prepared in GraphPad Prism (version 5, GraphPad
Software). Results are given as “mean [se]”, except GDF11, which
is given as “median [lower–upper quartile].”
RESULTS
FLRG Differs between Younger and Older
Individuals
To establish the effect of age on the concentration of myostatin
and myostatin-interacting peptides, plasma from younger and
older individuals was used. A two-way mixed model (age ×
peptide state) ANOVA showed no interaction for myostatin
(p = 0.610), nor an effect of age (p = 0.771). As expected, a
significant effect of peptide state is seen (free 1618.9 [125.9], total
3664.1 [247.1] pg.mL−1; p < 0.001; Figure 1A).
Plasma activin A was significantly higher in older individuals
(younger 215.9 [20.2], older 291.6 [21.0] pg.mL−1; p = 0.026;
Figure 1B), as was plasma FLRG (younger 4731.6 [522.5], older
9915.8 [975.1] pg.mL−1; p <0.001; Figure 1C). No difference in
GDF11 was seen between groups (younger 388.4 [274.9–6339.8],
older 219.4 [143.2–6694.8]; p= 0.394; Figure 1D).
Cells Grown in Younger Plasma Show a
Protective Effect
C2C12 cells were stimulated with standard GM or DM +
5% older or younger plasma for varying lengths of time
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FIGURE 1 | Concentration of plasma endocrine factors from younger and older participants. (A) Myostatin (free and total), (B) activin A, (C) FLRG, and (D) GDF-11 (all
pg.mL−1). Data are presented as grouped dot plots, with horizontal lines indicated mean in panels (A–C), median in panel (D). Note panel (D) is presented on a
logarithmic y axis. N = 6 per group, closed circles indicate younger, open squares older participants. *Indicates significant differences as marked.
before proliferation, scratch damage recovery and differentiation
capacity was assessed.
No age × time interaction was seen on the proliferation
capacity of cells (p= 0.535), nor a main effect of age (p= 0.367).
As expected, there was a main effect of time witnessed, with
significantly more cells present at 48 h, relative to 24 h (p <0.001;
Figure 2A).
When cells were scratched and then allowed to regenerate
for 4 h, post scratch size was smaller in the younger relative to
the older condition (younger 78.2 [2.2], older 87.2 [2.7]% of
baseline; p = 0.0281; Figure 2B, representative images shown in
Figure 2C).
Following replacement with conditioned media, myotube
cell diameters showed a significant age × time interaction
(p = 0.008). Specifically, post hoc testing suggested younger cells
were larger at 24 (26.8 [0.5] vs. 23.4 [0.5] pixels; p < 0.05) and
48 h (28.3 [0.3] vs. 22.5 [1.6] pixels; p < 0.05; Figure 2D).
A significant correlation was noted between myotube
diameter at 48 h and the plasma concentration of FLRG,
independent of participant age (r2 = 0.392, p= 0.030; Figure 3),
but not for activin A (r2 = 0.123, p= 0.264). No correlations were
noted between scratch closure and FLRG or activin A.
DISCUSSION
In line with our hypothesis, here we demonstrate that
plasma from older individuals induces both reduced myoblasts
migration and a reduced myotube diameter, both relative to
those stimulated with younger plasma. The primary endocrine
difference reported here between younger and older individuals
was in the myostatin and GDF11 inhibitor FLRG, thus it is also
of interest to note that circulating FLRG concentration in vivo
correlated with the individual myotube diameter response in
vitro. However, no difference in GDF11, free myostatin or total
myostatin plasma concentration was noted between ages.
By utilising C2C12 myoblasts as a “clean” cell line,
independent of ageing effects, the effects we see from plasma
conditioning of cellular media and subsequent stimulation of
C2C12 cells can be deduced to be plasma-dependent. We
developed this model on the observation that mixed results have
been reported for an ageing effect on satellite cells and muscle
functionality. Indeed, where human primary muscle cells grown
in vitro from both younger (23–25 years of age) and older
donors (67–82) do not show proliferation, fusion or myotube
size differences (Alsharidah et al., 2013), primary culture from
older average (78.5 years of age) show reduced myotube fusion
(Pietrangelo et al., 2009). Whilst the age of older groups was
similar, these samples were taken from hip replacement surgery
patients, thus who are likely to have experienced extended disuse
prior to biopsy collection, possibly explaining differences in
results. These observations lead us to hypothesise that endocrine
environment differences may underlie differences in muscle
mass and function between ages, and indeed the results that
we present here suggest this to be the case. However, purely
endocrine factors cannot completely explain loss of muscle
mass and function with ageing. Alterations in mitochondrial
reactive oxygen species (Desler et al., 2011), altered mechanical
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FIGURE 2 | Effect of plasma conditioned media on myoblast proliferation, migration, and myotube size in vitro. (A) Proliferation rate of cells at 24 and 48 h, (B) scratch
closure (% of baseline) 4 h post scratch, with (C) showing representative images. Note edges have been highlighted for publication. (D) myotube diameters. Horizontal
lines in (A,B) indicate group means. Error bars in (D) indicate standard error. N = 6 per group, closed circles indicate younger, open squares older participants.
*Indicates significant differences as marked in (A,B), significant difference between older vs. younger group at marked time-point in (D). Younger/Older conditions
represent cell GM (A–C) or DM (D) conditioned with 5% plasma from younger or older individuals, respectively.
stimulation of muscle satellite cells (Boers et al., 2017), alterations
in physical activity (Daskalopoulou et al., 2017) and increased
low level inflammation (Franceschi and Campisi, 2014) are likely
to interact to impair successful ageing and the preservation of
muscle mass with age.
The in vivo parallel to the myoblast scratch assay we report
here is most likely muscular injury and recovery. In this light, it is
interesting to note that older individuals show anabolic resistance
to amino acid feeding (Cuthbertson et al., 2005), reduced rates
of satellite cells per muscle fibre (Verdijk et al., 2007), and
reduced muscle recovery following immobilisation-retraining
(Suetta et al., 2009), ultimately resulting in a proposed reduced
rate of injury repair and recovery (Fell and Williams, 2008)
and increased intermuscular fibrosis and adipose tissue, and a
reduced muscle force output (Alnaqeeb et al., 1984; Delmonico
et al., 2009). Whilst speculative at this point, the endocrine
mechanistic reduction in scratch-recovery in our in vitro older
condition may in part reflect the early stages of this process.
Myotube diameter was reduced in our older condition,
relative to the younger. Myostatin, GDF11 and activin A have
all been demonstrated to inhibit myoblast differentiation in
vitro (Souza et al., 2008), whilst follistatin and FLRG can be
used to promote fusion, but indirectly via myostatin-dependent
FIGURE 3 | Myotube diameter at 48 h post plasma stimulation as a function of
in vivo plasma concentration of FLRG (pg.mL−1). Linear regression indicated,
independent of age group. Closed circles indicate younger, open squares
older participants.
myotube inhibition (Hill et al., 2002; Iezzi et al., 2004). With
no difference in myostatin or GDF11, we would suggest that
the either increased activin A concentration has resulted in
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reduced fusion in the older group, or the increase in FLRG in
the older group is impairing myoblast fusion, as implied by the
moderate correlation we report between myotube size and FLRG
concentration. This second hypothesis seems initially unlikely, as
FRLG has been demonstrated to bind and inhibit myostatin in
vivo (Hill et al., 2002), in a similar manner to the closely related
follistatin (Amthor et al., 2004), which should be expected to
increase myotube size, not decrease as we report here. To the
best of our knowledge, the direct effect of FLRG on myoblast
proliferation and differentiation has not been directly examined
in vitro, however it is interesting to note that FLRG does directly
inhibit osteoclast fusion and differentiation (Bartholin et al.,
2005).
Whilst not a primary aim of this in vitro experiment, is
it noteworthy to report that both total and free myostatin
appear to circulate at similar concentrations between younger
and older individuals in the limited sample size collected here,
despite the later having significantly reduced skeletal muscle
mass. Similar results have been reported previously for plasma
total myostatin in younger healthy males vs. older sarcopenic
males (Ratkevicius et al., 2011), however we further these results
with the addition of free myostatin. The same paper reports
a trend toward a difference in FLRG concentration between
younger and older individuals, whist both Bergen et al. (2015)
and our results presented here suggest FLRG is increased in
older individuals. The correlative relationship that we report here
between circulating FLRG in vivo and myotube diameter in vitro
is suggestive of a physiological relationship between the two.
Much recent attention has been placed on ageing and GDF11,
with reports that GDF11 decreases with age in mice, and
restoration of “younger” levels ameliorates age-related declines in
muscular function (Sinha et al., 2014). Further, highly active older
individuals show increased levels of GDF11 over inactive older
individuals (Elliott et al., 2017). Whilst we report no difference
between younger and older individuals here in both myostatin
and GDF11, we do acknowledge the study was not powered for
this outcome. However, it is of interest to note that the age groups
do have similar concentration ranges of these peptides, despite
the significant difference in muscle mass seen. It is tempting to
infer a sensitivity to the effects of circulating myostatin/GDF11
may be seen in older individuals, helping explain this apparent
contradiction, however further work would be needed to state
this. Other TGF-β family members have been suggested to
contribute to human ageing, and here our results show an
increase in activin A, confirming prior findings (Baccarelli et al.,
2001).
Whilst not measured here, it should be acknowledged that
a large number of endocrine factors are suggested to change
with human ageing. These include classic anabolic factors such
as growth hormone, insulin and IGF (Ratkevicius et al., 2011;
Sellami et al., 2017), as well as the likely catabolic, low level of pro-
inflammatory cytokines such as tumour necrosis factor alpha and
interleukin 1 beta (Ferrucci et al., 2005; Alvarez-Rodríguez et al.,
2012). Further, more recently identified factors such as Klotho act
in an endocrine manner in mice and appear to regulate lifespan
(Kurosu et al., 2005). A complete picture of endocrinology of
aging may need to consider these factors.
CONCLUSIONS
In conclusion, here we demonstrate that plasma from older
individuals both inhibits myoblast migration and reduces
myotube diameter, relative to younger plasma. These effects
appear independent of circulating myostatin and GDF11,
however may involve activin-family peptide inhibitor FLRG.
Whilst our results show part of ageing-related changes in muscle
mass may be endocrine in nature, the interaction between this
observation and other aspects of ageing need to be further
explored. Further work is needed to examine the effect of
increased FLRG concentration on muscle function in ageing
populations.
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